A Monoclonal Antibody against the c-erbB-2 Protein Enhances the Cytotoxicity of cis-Diamminedichloroplatinum against Human Breast and Ovarian Tumor Cell Lines

Cancer Research

Volumn 51, Issue 17, 1991, Pages 4575-4580

  Hancock, M C ^a,b   Chan, T ^a,b   Monahan, J J ^a,b   Toy, P ^a,b   Mischak, R P ^a   Shawver, L K ^a  

^a BAYER AG   (Germany)

^b Somatix Therapy Inc ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY TAB 250; ONCOPROTEIN; UNCLASSIFIED DRUG;

ARTICLE; BREAST CANCER; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG POTENTIATION; FEMALE; HUMAN; HUMAN CELL; OVARY CANCER; PRIORITY JOURNAL; TUMOR CELL LINE;

ANIMAL; ANTIBODIES, MONOCLONAL; BREAST NEOPLASMS; CELL DIVISION; CELL LINE; CISPLATIN; DRUG SYNERGISM; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMAN; MICE; MICE, INBRED BALB C; OVARIAN NEOPLASMS; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENES; RECEPTOR, ERBB-2;

EID: 0025986825     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: None     Document Type: Article

References (31)

1. DiFiore, P. P., Pierce, J. H., Kraus, M. H., Segatto, O., King, R., and Aaronson, S. A. erbB-1 is a potent oncogene when overexpressed in NIH/ 3T3 cells. Science (Washington DC), 237: 178-181, 1987.
2. Hudziak, R. M., Schlessinger, J., and Ullrich, A. Increased expression of the putative growth factor receptor pl8SHER2 causes transformation and tumorigenesis of NIH 3T3 cells. Proc. Natl. Acad. Sci. USA, 84: 7159-7163, 1987.
3. King, C. R., Kraus, M. H., and Aaronson, S. A. Amplification of a novel v-erb-related gene in a human mammary carcinoma. Science (Washington DC), 229: 974-976, 1985.
4. Kraus, M. H., Popescu, N. C., Amsbaugh, S. C., and King, C. R. Overexpression of the EGF receptor-related proto-oncogene erbB-2 in human mammary tumor cell lines by different molecular mechanisms. EMBO J., 6: 605-610, 1987.
5. van de Vijver, M., van de Bersselaar, R., Devilee, P., Comelisse, C., Peterse, J., and Nusse, R. Amplification of the neu (c-verb) oncogene in human mammary tumors is relatively frequent and is often accompanied by amplification of the linked c-erbA oncogene. Mol. Cell Biol., 7:2019-2023, 1987.
6. Natali, P. G., Nicotra, M. R., Bigotti, A., Venturo, I., Slamon, D. J., Fendly, B. M., and Ullrich, A. Expression of the pi 85 encoded by HER2 oncogene in normal and transformed human tissues. Int. J. Cancer, 45:457-461, 1990.
7. Berchuck, A., Kamel, A., Whitaker, R., Kerns, B., Olt, G., Kinney, R., Soper, J. T., Dodge, R., Clarke-Pearson, D. L., and Marks, P. Overexpression of HER-2/neu is associated with poor survival in advanced epithelial ovarian cancer. Cancer Res., 50:4087-4091, 1990.
8. Semba, K., Kamata, N., Toyoshima, K., and Yamamoto, T. A v-erb-related protooncogene, c-erbB-2, is distinct from the c-erbB-1/epidermal growth factor-receptor gene and is amplified in a human salivary gland adenocarcinoma. Proc. Natl. Acad. Sci. USA, 82:6497-6501, 1985.
9. Yokota, T., Yamamoto, T., Miyajima, N., Toyoshima, K., Nomura, N., Sakamoto, H., Yoshida, T., Terada, M., and Sugimura, T. Genetic alterations of the c-erbB-2 oncogene occur frequently in tubular adenocarcinoma of the stomach and are often accompanied by amplification of the v-erb homo-logue. Oncogene, 2: 283-287, 1988.
10. Slamon, D. J., Clark, G. M., Wong, S. G., Levin, W. J., Ullrich, A., and McGuire, W. L. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science (Washington DC), 235: 177-182, 1987.
11. DePotter, C. R., Quatacker, J., Maertens, G., Van Daele, S., Pauwels, C., Verhofstede, C., Eechaute, W., and Roels, H. The subcellular localization of the neu protein in human normal and neoplastic cells. Int. J. Cancer, 44: 969-974, 1989.
12. Maguire, H. C., Jaworsky, C., Cohen, J. A., Heilman, M., Weiner, D. B., and Greene, M. I. Distribution of neu (c-erbB-2) protein in human skin. J. Invest. Dermatol., 92: 786-790, 1989.
13. Cohen, J. A., Weiner, D. B., More, K. F., Kokai, Y., Williams, W. V., Maguire, H. C., Jr., LiVolsi, V. A., and Greene, M. I. Expression pattern of the neu (NGL) gene-encoded growth factor receptor protein (pl85neu) in normal and transformed epithelial tissues of the digestive tract. Oncogene, 81-88, 1989.
14. Drebin, J. A., Link, V. C., Stem, D. F., Weinberg, R. A., and Greene, M. I. Down-modulation of an oncogene protein product and reversion of the transformed phenotype by monoclonal antibodies. Cell, 41:695-706, 1985.
15. Hudziak, R. M., Lewis, G. D., Winget, M., Fendly, B. M., Shepard, H. M., and Ullrich, A. Monoclonal antibody has antiproliferative effects in vitro and sensitizes human breast tumor cells to tumor necrosis factor. Mol. Cell. Biol., 9: 1165-1172, 1989.
16. Chabner, B. A., and Myers, C. E. Clinical Pharmacology of Cancer Chemotherapy. In: V. T. DeVita, Jr., S. Mellman, and S. A. Rosenberg (eds.). Cancer, Principles and Practice of Oncology, Ed. 3, Vol. 1, pp. 349-395. Philadelphia: J. B. Lippincott Co., 1989.
17. McClay, E. F., and Howell, S. B. A review: intraperitoneal cisplatin in the management of patients with ovarian cancer. Gynecol. Oncol., 36:1-6, 1990.
18. Langton, B. C., Crenshaw, M. C., Chao, L. A., Stuart, S. G., Akita, R. W., and Jackson, J. E. An antigen immunologically related to the external domain of gpl85 is shed from nude mouse tumors overexpressing the c-erbB-2 (HER-2/neu) oncogene. Cancer Res., 51:2593-2598, 1991.
19. Mosmann, T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J. Immunol. Methods, 65: 55-63, 1983.
20. SAS Institute Inc. SAS/STAT User's Guide, Version 6, Ed. 4, Vol. 2. Cary, NC: SAS Institute, 1989.
21. Filmus, J., Pollak, M. N., Cailleau, R., and Buick, R. N. MDA-468, a human breast cancer cell line with a high number of epidermal growth factor (EGF) reeptors, has an amplified EGF receptor gene and is growth inhibited by EGF. Biochem. Biophys. Res. Commun., 128:898-905, 1985.
22. Aboud-Pirak, E., Hurwitz, E., Pirak, M. E., Bellot, F., Schlessinger, J., and Sela, M. Efficacy of antibodies to epidermal growth factor receptor against KB carcinoma in vitro and in nude mice. J. Natl. Cancer Inst., 21: 1605-1611, 1988.
23. Shionoya, S., Lu, Y., and Scanlon, K. J. Properties of amino acid transport systems in K562 cells sensitive and resistant to cis-diamminedichloropla-tinum(II). Cancer Res., 46: 3445-3448, 1986.
24. Gross, R. B., and Scanlon, K. J. Amino acid membrane transport properties of LI 210 cells resistant to cisplatin. Chemioterapia, 5: 37-43, 1986.
25. Hofmann, J., Doppler, W., Jakob, A., Maly, K., Posch, L., Uberall, F., and Grunicke, H. H. Enhancement of the antiproliferative effect of cis-diammi-nedichloroplatinum(II) and nitrogen mustard by inhibitors of protein kinase C. Int. J. Cancer, 42:382-388, 1988.
26. Hofmann, J., Ueberall, F., Posch, L., Maly, K., Herrmann, D. B. J., and Gninicke, H. Synergistic enhancement of the antiproliferative activity of cis-diamminedichloroplatinum(II) by the ether lipid analogue BM41440, an inhibitor of protein kinase C. Lipids, 24:312-317, 1989.
27. Hollander, M. C., and Fornace, A. J., Induction of fos RNA by DNA-i damaging agents. Cancer Res., 49:1687-1692, 1989.
28. Scanlon, K. J., Lu, Y., Kashani-Sabet, M., Ma, J., and Newman, E. Mechanisms for cisplatin-Fura synergism and cisplatin resistance in human ovarian : carcinoma cells both in vitro and in vivo. The expanding role of folates and fluoropyrimides in cancer chemotherapy. Adv. Exp. Med. Biol., 244: 127-135, 1988.
29. James, M. R., and Lehmann, A. R. Role of poly(adenosine diphosphate ribose) in DNA repair in human fibroblasts. Biochemistry, 21: 4007-4012, 1982.
30. Yamamoto, H., and Okamoto, H. Poly(ADP-ribose) synthetase inhibitors enhance streptozotocin-induced killing of insulinoma cells by inhibiting the repair of DNA strand breaks. FEBS Lett., 145:298-303, 1982.
31. Huet, J., and Laval, F. Potentiation of cell killing by inhibitors of poly(adenosine diphosphate-ribose) synthesis in bleomycin-treated Chinese hamster ovary cells. Cancer Res., 45:987-993, 1985.